Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Zou, Yong ^a   Ma, Xudong ^a   Huang, Yiqun ^a   Hong, Lingling ^a   Chiao, Jen Wei ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Histone; Leukemia; Methylation; Phenylhexyl isothiocyanate (PHI)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; METHYLTRANSFERASE; PHENYLHEXYL ISOTHIOCYANATE; PROTEIN HISTONE H3 LYSINE 4; PROTEIN HISTONE H3 LYSINE 9; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MALE; MYELOID LEUKEMIA; PRESCHOOL CHILD; PROTEIN METHYLATION; SCHOOL CHILD;

ACETYLATION; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CASE-CONTROL STUDIES; CHILD; DNA METHYLATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; HYDROXAMIC ACIDS; ISOTHIOCYANATES; LEUKEMIA; MALE; MIDDLE AGED; PROTEIN PROCESSING, POST-TRANSLATIONAL; YOUNG ADULT;

EID: 84863112741     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-36     Document Type: Article

References (38)

1. Translating the histone code. Jenuwein T, Allis CD, Science 2001 293 5532 1074 1080 (Pubitemid 32758077)
2. The language of covalent histone modifications. Strahl BD, Allis CD, Nature 2000 403 6765 41 45 (Pubitemid 30038513)
3. Loss of acetylation at lys 16 and trimethylation at lys 20 of histone H4 is a common hallmark of human cancer. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M, Nat Genet 2005 37 4 391 400
4. Linking the epigenetic 'language' of covalent histone modifications to cancer. Hake SB, Xiao A, Allis CD, Br J Cancer 2004 90 4 761 769 (Pubitemid 38406583)
5. Mechanisms of transformation by MLL. Hess JL, Crit Rev Eukaryot Gene Expr 2004 14 4 235 254 (Pubitemid 40221055)
6. Unsafe SETs: histone lysine methyltransferases and cancer. Schneider R, Bannister AJ, Kouzarides T, Trends Biochem Sci 2002 27 8 396 402 (Pubitemid 34874749)
7. PLU-1 is an H3K4 demethylase involved n transcriptional repression and breast cancer cell. Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, Zhang Y, Mol Cell 2007 25 6 801 812 (Pubitemid 46436533)
8. Histones and histone modifications. Peterson CL, Laniel M, Curr Biol 2004 14 14 546 R551
9. Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Sanders SL, Portoso M, Mata J, Bahler J, Allshire RC, Kouzarides T, Cell 2004 119 5 603 614 (Pubitemid 39535749)
10. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Zhang Y, Reinberg D, Genes Dev 2001 15 18 2343 2360 (Pubitemid 32899739)
11. Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Boggs BA, Cheung P, Heard E, Spector DL, Chinault AC, Allis CD, Nat Genet 2002 30 1 73 76
12. Histone H3 lysine 4 methylation is mediated by Set1 and prmotes maintenance of active chromatin states in fission yeast. Noma KI, Grewal SI, Proc Natl Acad Sci U S A 2002 4 16438 16445 (Pubitemid 35470991)
13. The many faces of histone lysine methylation. Lachner M, Jenuwein T, Curr Opin Cell Biol 2002 14 3 286 298 (Pubitemid 34626966)
14. JmjC-domain- containing proteins and histone demethylation. Klose RJ, Kauin EM, Zhang Y, Nat Rev Genet 2006 7 9 715 727 (Pubitemid 44260007)
15. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. Cang SD, Ma YH, Liu DL, J Hematol Oncol 2009 2 22
16. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Tan JH, Cang SD, Ma YH, Petrillo RL, Liu DL, J Hematol Oncol 2010 3 5
17. The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Lu LL, Liu DL, Ma XD, Beklemishev A, Seiter K, Ahmed T, Chiao JW, Oncol Rep 2006 16 6 1363 1367
18. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatin to induce growth arrest in human leukemia cells. Ma XD, Fang YQ, Beklemisheva A, Dai W, Feng JY, Ahmed T, Liu DL, Chiao JW, Int J Oncol 2006 28 5 1287 1293
19. Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. Lu QY, Lin XH, Feng J, Zhao XM, Gallagher R, Lee MY, Chiao JW, Liu DL, J Hematol Oncol 2008 1 6
20. Deficient Histone Acetylation in Acute Leukemia and the Correction by an Isothiocyanate. Xiao LY, Huang YQ, Zhen RJ, Chiao JW, Liu DL, Ma XD, Acta Haematol 2010 123 2 71 76
21. Experimental study of PHI on methylation and acetylation in Molt-4T cells. Huang YQ, Ma XD, Zhen RJ, Chiao JW, Liu DL, Zhonghua Xue Ye Xue Za Zhi 2007 28 9 612 615
22. Histone H3-lysine 9 methylation is associated with aberrant gene selincing in cancer cells and is rapidly reversed by 5-aza-2deoxycytidine. Nguyen CT, Wisenberger DJ, Velicescu M, Conzales FA, Lin JC, Liang G, Jones PA, Cancer Res 2002 62 22 6456 6461 (Pubitemid 35364106)
23. Distribution of methylated histone and histone methyltransferases in chicken erythrocyte chromatin. Hendzel MJ, Davie JR, J Biol Chem 1989 264 32 19208 19214 (Pubitemid 19285831)
24. Relationship between methylation and acetylation of arginine-rich histone in cycling and arrested Hela cells. Annunziato AT, Eason MB, Perry CA, Biochemistry 1995 34 9 2916 2924
25. Phenylhexyl isothiocyanate induces gene p15 demethylation by down-regulating DNA methyltransferases in molt-4 cells. Jiang SH, Ma XD, Huang YQ, Xu YL, Zheng RJ, Yao Xue Xue Bao 2009 44 4 350 354
26. Histone methyltransferases: regulation of transcription and contribution to human disease. Nimura K, Ura K, Kaneda Y, J Mol Med 2010 88 12 1213 1220
27. The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E, Proc Natl Acad Sci U S A 1998 95 8 4152 4157 (Pubitemid 28207880)
28. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y, Nat Cell Biol 2004 6 8 731 740 (Pubitemid 39144478)
29. Set domain-containing protein, G9a, is a novel lysinepreferring mammalian histone methyltran-sferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. Tachibana M, Sugimoto K, Fukushima T, Shinkai Y, J Biol Chem 2001 276 27 25309 25317
30. Loss of the Suv39h histone methyltransferases impairsmammalian heterochromatin and genome stability. Peters AH, O' Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, Sibilia M, Jenuwein T, Cell 2001 107 3) 323 337 (Pubitemid 33049976)
31. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ, Genes Dev 2002 16 8 919 932 (Pubitemid 34408542)
32. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Yang L, Xia L, Wu DY, Wang H, Chansky HA, Schubach WH, Hickstein DD, Zhang Y, Oncogene 2002 21 1 148 152 (Pubitemid 34076387)
33. 5-azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Christman JK, Oncogene 2002 21 35 5483 5495 (Pubitemid 34983483)
34. Novel targeted therapeutics: inhibitors of MDM2. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR, ALK and PARP. J Hematol Oncol 2011 4 16
35. Targeted therapy in lymphoma. Johnston PB, Yuan R, Cavalli F, Witzig TE, J Hematol Oncol 2010 3 1 45
36. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. Zhu XP, Ma YH, Liu DL, J Hematol Oncol 2010 3 1 17
37. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. Frémin C, Meloche S, J Hematol Oncol 2010 3 1 8
38. Digitoxin and its analogs as novel cancer therapeutics. Elbaz HA, Stueckle TA, Tse W, Rojanasakul Y, Dinu CZ, Exp Hematol Oncol 2012 1 1 4